FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387185622> ?p ?o ?g. }

• W4387185622 endingPage "4786" @default.
• W4387185622 startingPage "4786" @default.
• W4387185622 abstract "Primary immunodeficiencies (PIDs) and secondary immunodeficiencies (SIDs) are characterized by compromised immune function, rendering individuals susceptible to infections and potentially influencing cancer development. Epstein-Barr virus (EBV), a widespread herpesvirus, has been linked to cancer, particularly in those with weakened immune systems. This study aims to compare selected immune parameters, focusing on immune checkpoint molecules (PD-1/PD-L1, CTLA-4/CD86, CD200R/CD200), and EBV reactivation in patients with chronic lymphocytic leukemia (CLL, a representative of SIDs) and common variable immunodeficiency (CVID, a representative of PIDs). We performed a correlation analysis involving patients diagnosed with CLL, CVID, and a healthy control group. EBV reactivation was assessed using specific antibody serology and viral load quantification. Peripheral blood morphology, biochemistry, and immunophenotyping were performed, with emphasis on T and B lymphocytes expressing immune checkpoints and their serum concentrations. Our findings revealed elevated EBV reactivation markers in both CLL and CVID patients compared with healthy controls, indicating increased viral activity in immunodeficient individuals. Furthermore, immune checkpoint expression analysis demonstrated significantly altered percentages of T and B lymphocytes expressing PD-1/PD-L1, CTLA-4/CD86, and CD200R/CD200 in CLL and CVID patients. This suggests a potential interplay between immune checkpoint dysregulation and EBV reactivation in the context of immunodeficiency. In conclusion, our study underscores the intricate relationship between immune dysfunction, EBV reactivation, and immune checkpoint modulation in the context of immunodeficiency-associated cancers. The altered expression of immune checkpoints, along with heightened EBV reactivation, suggests a potential mechanism for immune evasion and tumor progression. These findings provide insights into the complex interactions that contribute to cancer development in immunocompromised individuals, shedding light on potential therapeutic targets for improved management and treatment outcomes. Further investigations are warranted to elucidate the underlying mechanisms and to explore potential interventions to mitigate cancer risk in these patient populations." @default.
• W4387185622 created "2023-09-30" @default.
• W4387185622 creator A5013521878 @default.
• W4387185622 creator A5014807657 @default.
• W4387185622 creator A5022273551 @default.
• W4387185622 creator A5028251491 @default.
• W4387185622 creator A5034819812 @default.
• W4387185622 creator A5036633111 @default.
• W4387185622 creator A5061121227 @default.
• W4387185622 creator A5081754515 @default.
• W4387185622 creator A5086068979 @default.
• W4387185622 creator A5092968789 @default.
• W4387185622 date "2023-09-29" @default.
• W4387185622 modified "2023-10-17" @default.
• W4387185622 title "Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?" @default.
• W4387185622 cites W100568664 @default.
• W4387185622 cites W1832647961 @default.
• W4387185622 cites W1969179435 @default.
• W4387185622 cites W1979841260 @default.
• W4387185622 cites W1985508003 @default.
• W4387185622 cites W2000550695 @default.
• W4387185622 cites W2028749680 @default.
• W4387185622 cites W2030552690 @default.
• W4387185622 cites W2033700044 @default.
• W4387185622 cites W2034507166 @default.
• W4387185622 cites W2041098436 @default.
• W4387185622 cites W2043433501 @default.
• W4387185622 cites W2055630249 @default.
• W4387185622 cites W2056519855 @default.
• W4387185622 cites W2061267724 @default.
• W4387185622 cites W2112956340 @default.
• W4387185622 cites W2193388945 @default.
• W4387185622 cites W2401113962 @default.
• W4387185622 cites W2522340012 @default.
• W4387185622 cites W2547565004 @default.
• W4387185622 cites W2563543508 @default.
• W4387185622 cites W2594001971 @default.
• W4387185622 cites W2606741370 @default.
• W4387185622 cites W2742446628 @default.
• W4387185622 cites W2780710194 @default.
• W4387185622 cites W2790247213 @default.
• W4387185622 cites W2790663567 @default.
• W4387185622 cites W2793182605 @default.
• W4387185622 cites W2802259287 @default.
• W4387185622 cites W2804232833 @default.
• W4387185622 cites W2805029378 @default.
• W4387185622 cites W2884317633 @default.
• W4387185622 cites W2912809137 @default.
• W4387185622 cites W2914467765 @default.
• W4387185622 cites W2936035861 @default.
• W4387185622 cites W2942291543 @default.
• W4387185622 cites W2959497269 @default.
• W4387185622 cites W3005180546 @default.
• W4387185622 cites W3005664313 @default.
• W4387185622 cites W3010496793 @default.
• W4387185622 cites W3013203042 @default.
• W4387185622 cites W3042934496 @default.
• W4387185622 cites W3095756504 @default.
• W4387185622 cites W3103912714 @default.
• W4387185622 cites W3118775651 @default.
• W4387185622 cites W3133339554 @default.
• W4387185622 cites W3155878711 @default.
• W4387185622 cites W3169302268 @default.
• W4387185622 cites W3205770224 @default.
• W4387185622 cites W3206315567 @default.
• W4387185622 cites W3210299993 @default.
• W4387185622 cites W3212318746 @default.
• W4387185622 cites W4200119136 @default.
• W4387185622 cites W4210512024 @default.
• W4387185622 cites W4211245347 @default.
• W4387185622 cites W4213029195 @default.
• W4387185622 cites W4214810944 @default.
• W4387185622 cites W4220673743 @default.
• W4387185622 cites W4237163879 @default.
• W4387185622 cites W4283158439 @default.
• W4387185622 cites W4283522643 @default.
• W4387185622 cites W4285588062 @default.
• W4387185622 cites W4285726146 @default.
• W4387185622 cites W4297257072 @default.
• W4387185622 cites W4307632183 @default.
• W4387185622 cites W4323850604 @default.
• W4387185622 cites W4327962983 @default.
• W4387185622 cites W4362474475 @default.
• W4387185622 cites W4378193760 @default.
• W4387185622 doi "https://doi.org/10.3390/cancers15194786" @default.
• W4387185622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37835480" @default.
• W4387185622 hasPublicationYear "2023" @default.
• W4387185622 type Work @default.
• W4387185622 citedByCount "0" @default.
• W4387185622 crossrefType "journal-article" @default.
• W4387185622 hasAuthorship W4387185622A5013521878 @default.
• W4387185622 hasAuthorship W4387185622A5014807657 @default.
• W4387185622 hasAuthorship W4387185622A5022273551 @default.
• W4387185622 hasAuthorship W4387185622A5028251491 @default.
• W4387185622 hasAuthorship W4387185622A5034819812 @default.
• W4387185622 hasAuthorship W4387185622A5036633111 @default.
• W4387185622 hasAuthorship W4387185622A5061121227 @default.
• W4387185622 hasAuthorship W4387185622A5081754515 @default.

• next